J P Morgan Chase & Co restated their neutral rating on shares of BTG (LON:BTG) in a research note published on Friday morning.

Other analysts also recently issued research reports about the stock. Peel Hunt reiterated a hold rating and issued a GBX 680 ($9.15) target price on shares of BTG in a report on Tuesday, November 14th. Numis Securities restated a buy rating and set a GBX 900 ($12.11) price target on shares of BTG in a research report on Wednesday, September 20th. Finally, Deutsche Bank restated a buy rating and set a GBX 775 ($10.43) price target on shares of BTG in a research report on Friday, October 13th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. BTG currently has an average rating of Buy and an average target price of GBX 771.63 ($10.39).

BTG (LON:BTG) opened at GBX 741 ($9.97) on Friday. BTG has a 1-year low of GBX 528.36 ($7.11) and a 1-year high of GBX 779 ($10.48).

BTG (LON:BTG) last released its quarterly earnings data on Tuesday, November 14th. The company reported GBX 21 ($0.28) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of GBX 21 ($0.28). The firm had revenue of £341.30 million for the quarter. BTG had a net margin of 15.50% and a return on equity of 10.80%.

WARNING: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/btgs-btg-neutral-rating-reaffirmed-at-j-p-morgan-chase-co/1758489.html.

BTG Company Profile

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Analyst Recommendations for BTG (LON:BTG)

Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.